Report Company Directory

Sio Gene Therapies Inc

• Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share by GlobeNewsWire
• Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results by GlobeNewsWire
• Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution by GlobeNewsWire
• Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results by GlobeNewsWire
• Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results by GlobeNewsWire
• Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results by GlobeNewsWire
• Sio Gene Therapies Provides Corporate Update by GlobeNewsWire
• Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results by GlobeNewsWire
• Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022 by GlobeNewsWire
• Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition by GlobeNewsWire

Sio Gene Therapies Inc

• InsiderInsights Weekly Tables: July 25, 2020 by InsiderInsights.com
• InsiderInsights Weekly Tables: July 18, 2020 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: July 10, 2020 by InsiderInsights.com
• InsiderInsights Daily Ratings Report: February 27, 2020 by InsiderInsights.com

Sio Gene Therapies Inc

• Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis by GlobeNewsWire
• Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor by GlobeNewsWire
• Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020 by GlobeNewsWire
• Axovant Gene Therapies Announces Name Change to Sio Gene Therapies by GlobeNewsWire
• Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases by GlobeNewsWire
• Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020 by GlobeNewsWire
• Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020 by GlobeNewsWire
• Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease by GlobeNewsWire
• Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis by GlobeNewsWire
• Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer by GlobeNewsWire

Sioen Industries N.V.

• Morning Note: BPOST BB, COFB BB, DSM NA, GIMB BB, KIN BB, SIOE BB, SOLB BB, TNET BB, UMI BB, XFAB FP by KBC Securities
• Monthly LMI Update Independent Investment Research by Independent Investment Research
• Pauls large cap conference by KBC Securities
• [Enter Conference Name] by KBC Securities
• Benelux Morning Notes by ING Financial Markets
• Benelux Morning Notes by ING Financial Markets
• Morning Note: ARGX BB, BANI BB, BOKA NA, ENX FP, EVS BB, GLPG NA, SIOE BB, SMAR BB by KBC Securities
• Benelux Morning Notes by ING Financial Markets
• Morning Note: BEKB BB, ELI BB, MDXH BB, MELE BB, REC BB, SIOE BB, TINC BB by KBC Securities
• Sioen Industries/Takeover bid increased to €27 per share by ING Financial Markets

SIONIX CORP